Objective To evaluate the efficacy and safety of cefoperazone/sulbactam and levofloxacin in the treatment of community-acquired pneumonia(CAP). Methods 60 patients with CAP were randomly divided into two groups. Treatment group: the patients were treated with cefoperazone/sulbactam and levofloxacin. Control group: the patients were treated with cefoperazone/sulbactam alone. Both groups were treated for 10-14 days. To observe two groups of patients with clinical efficacy and adverse reaction. Results The total effective rate of treatment group was 96.75%, control group in the total efficiency was 84.56%, the results showed that there were significant differences between the two groups (P<0.05); the rates of the side effects were 10.79%and 8.36%. There were no significant differences between the two groups (P>0.05). Conclusion Cefoperazone/sulbactam and levofloxacin in the treatment of community-acquired pneumonia(CAP) can improve the curative effect, and well tolerated.% 目的观察头孢哌酮-舒巴坦联合左氧氟沙星治疗社区获得性肺炎（CAP）的临床疗效和不良反应。方法将60例 CAP 患者，随机分为两组，治疗组为头孢哌酮-舒巴坦联合左氧氟沙星组（n=30），对照组为单纯用头孢哌酮-舒巴坦（n=30，疗程均为10~14d，观察两组患者的临床疗效和不良反应。结果治疗组总有效率为96.75%，对照组的总有效率为84.56%，两组的临床疗效比较差异有统计学意义（P＜0.05）。治疗组不良反应发生率10.79%，对照组不良反应发生率8.36%，两组不良反应发生率比较差异无统计学意义（P ＞0.05）。结论头孢哌酮-舒巴坦联合左氧氟沙星治 CAP 可提高疗效，且耐受性良好。
展开▼
